FDA Reviewing Cardiovascular Effects of Osteoporosis Drugs

Drug Industry Daily
A A
The FDA is reviewing new safety data on reports of atrial fibrillation in patients taking bisphosphonates, which are typically used to treat osteoporosis, the agency announced. 

To View This Article:

Login

Subscribe To Drug Industry Daily